Compare Globus Medical Inc. Class A Common Stock (GMED) vs Royal Bank of Canada (RY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Royal Bank of Canada — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Royal Bank of Canada trades at $193.8 (market cap $268.76B). The key difference: Royal Bank of Canada is far larger — about 26.2× Globus Medical Inc. Class A Common Stock's market cap, and Royal Bank of Canada pays a 2.61% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Royal Bank of Canada for 48 Days on average.
| GMED | RY | |
|---|---|---|
Market Cap | $10.25B | $268.76B |
Volume | 1,108,124 | 1,509,016 |
Sector | Health | Financials |
52-Week High | $96.82 | $217.87 |
52-Week Low | $58.33 | $145.31 |
Typical Hold Time | 0 Days | 48 Days |
Enterprise Value | $9.76B | $738.98B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Royal Bank of Canada (RY) trades at $193.82, up 0.55% with a bearish technical signal despite strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $3.07 exceeding expectations. Revenue growth accelerated to $66.53B in 2025 with net income margin improving to 32.01%. Analyst consensus leans neutral with 43% buy ratings while technical indicators show resistance near $194.
RY presents a mixed outlook with robust profitability and dividend stability offset by stretched valuations and bearish technicals. The bank's 18% ROE and U.S. expansion provide upside potential, though high P/E of 17.5 and negative cash flow trends warrant caution. Near-term performance hinges on Q3 earnings due October 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
